Stocktoria
ENANTA PHARMACEUTICALS INC ENTA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-03-21
ENANTA PHARMACEUTICALS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -130.7% | -179.9% | -173.2% | -143.7% | -112.9% |
| Net margin | -125.4% | -171.6% | -169.0% | -141.3% | -81.4% |
| FCF margin | -49.2% | -143.0% | -141.7% | -100.9% | -72.9% |
| Return on assets | -29.2% | -30.8% | -28.9% | -32.4% | -18.0% |
| Return on equity | -126.5% | -90.1% | -61.7% | -37.9% | -19.8% |
| Current ratio | 4.21 | 5.21 | 6.73 | 10.45 | 8.82 |
| Revenue growth | -3.4% | -14.6% | -8.1% | -11.2% | -20.7% |
Source: SEC EDGAR filings · CIK 0001177648 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.